Bridge Biotherapeutics has partnered with Chinese drug discovery company HitGen to speed up the development of novel anticancer drugs. Financial and other details of the new agreement were undisclosed.
The partnership aims to leverage the companies’ expertise, technology, and resources to expand Bridge's oncology portfolio, based on the potent anticancer compounds from HitGen’s vast DNA-encoded library (DEL). The collaboration is expected to generate effective oncology treatments for genetically mutated forms of cancers that are considered challenging to address.
Bridge Biotherapeutics, headquartered in South Korea with offices in the US and China, is a clinical-stage biotechnology company focused on developing novel therapeutics for high unmet medical needs in cancer, fibrosis, and inflammatory diseases. The company's lead candidate, BBT-877, is a novel autotaxin inhibitor being evaluated in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF). Bridge Biotherapeutics is also advancing BBT-207, a fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), currently in trials for non-small-cell lung cancer (NSCLC) with EGFR C797S mutations.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.